Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls¹

Issue title: Alzheimer’s Disease: New Beginnings

Guest editors: G. Perry, J. Avila, P.I. Moreira, A.A. Sorensen and M. Tabaton

Article type: Review Article

Authors: Sigurdsson, Einar M.^{; *}

Affiliations: Departments of Neuroscience and Physiology, and Psychiatry, Neuroscience Institute, New York University School of Medicine, New York, NY, USA

Correspondence: [*] Correspondence to: Einar M. Sigurdsson, PhD, Departments of Neuroscience and Physiology, and Psychiatry, Neuroscience Institute, New York University School of Medicine, Science Building, 435 East 30th Street, New York, NY 10016, USA. E-mail: Einar.Sigurdsson@nyumc.org.

Note: [1] This article received a Correction published in Journal of Alzheimer’s Disease 66 (2018) 855–856, DOI 10.3233/JAD-189010, https://content.iospress.com/articles/journal-of-alzheimers-disease/jad189010.

Abstract: Tau immunotherapies have now advanced from proof-of-concept studies to Phase II clinical trials. This review briefly outlines developments in the field and discusses how these therapies may work, which involves multiple variables that are connected in complex ways. These various factors are likely to define therapeutic success in humans and have not been thoroughly investigated, at least based on published reports.

Keywords: Alzheimer’s disease, antibodies, clinical trials, immunotherapies, mechanisms, tau, tauopathy

DOI: 10.3233/JAD-179937

Journal: Journal of Alzheimer's Disease, vol. 64, no. s1, pp. S555-S565, 2018